Daily obesity tablets are widening the market for GLP-1 treatments and attracting new patients.
Analysts expect the sector to approach $200bn in value within the next decade.
Novo Nordisk has launched the first oral version of Wegovy in the US.
Early demand has been strong, with prescriptions rising faster than for earlier injections.
Patients switching from jabs report steadier appetite control and easier use.
Pills are cheaper, avoid needles and do not need refrigeration.
These advantages could make treatment more mainstream.
However, supply limits, side-effects and high out-of-pocket costs remain barriers.
Eli Lilly is preparing a rival tablet that may be simpler to absorb.
Competition is intensifying as more companies develop oral and combination therapies.
Injections still produce greater weight loss and will suit more severe cases.
Tablets are likely to attract people who are overweight or mildly obese.
Falling prices and broader insurance coverage are expected to expand access further.
With global obesity rising სწრაფly, drugmakers see the pill transition as a pivotal growth opportunity.
